Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2014 ACR/ARHP Annual Meeting: Bone Fracture Concerns in Children

Susan Bernstein  |  Issue: April 2015  |  April 1, 2015

Children and adolescents with pediatric rheumatic diseases may be at increased risk for fractures.
Image Credit: ChameleonsEye/shutterstock.com
Children and adolescents with pediatric rheumatic diseases may be at increased risk for fractures.

BOSTON—Children and adolescents with pediatric rheumatic diseases may be at increased risk for fractures and low bone-mass density, and rheumatologists should watch for signs of broken bones even in asymptomatic patients, an expert on pediatric rheumatic disease treatment told attendees at the ACR/ARHP Annual Meeting in Boston on Nov. 18, 2014.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Speaking on, Protecting Bone Health in Pediatric Rheumatic Diseases, Jon “Sandy” Burnham, MD, MSCE, clinical director of the Division of Rheumatology at the Children’s Hospital of Philadelphia, explored how bones develop and where problems may occur in kids in this patient population. Rheumatologists treating pediatric patients should appreciate the contributions of inflammation, glucocorticoid therapy and an altered body composition to lower bone mass and elevated fracture risk in this population, he said.

Careful monitoring, DXA and other imaging techniques, and bisphosphonates may help some pediatric rheumatic disease patients reduce fracture risk, Dr. Burnham said. Bisphosphonates are not FDA approved for use in pediatric patients, he noted.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Burnham
Dr. Burnham

Dr. Burnham began with the “cautionary tale” of one of his juvenile dermatomyositis patients, a 7-year-old girl who developed severe pain in her back and thigh two months after improving on her initial combination therapy, which included DMARDs and glucocorticoids. An MRI scan of her back revealed epidural lipomatosis and several vertebral compression fractures. Her steroids were tapered, and she was offered bisphosphonates, although her family initially rejected this treatment option, Dr. Burnham said.

 

Very Strong Structures

“Bones serve a variety of functions,” said Dr. Burnham. They are a bank for minerals, protect our internal organs and support our bodies’ movements with the minimum possible mass. “They are very strong structures. Even with the stupid risk-taking behaviors we all do as children, they really should not break.” Although most kids with rheumatic diseases will not experience a fracture, rheumatologists should watch for vertebral compression fractures even in patients who are asymptomatic, he said.

Several factors contribute to normal growth and skeletal development during childhood. Important bone boosters include normal nutrition, with recommended levels of vitamin D and calcium, and weight-bearing physical activity. “Bone adapts mechanical forces to maintain strain at a constant set point,” he said. Osteocytes sense the strain of activities and send effector signals that lead to the production of osteoblasts and osteoclasts, which regulate bone modeling.

Pediatric rheumatic disease patients face some unique challenges to healthy bone development, said Dr. Burnham.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersPediatric Conditions Tagged with:ACR/ARHP Annual MeetingBernsteinChildrenFracturesglucocorticoidGlucocorticoid-Induced OsteoporosisOsteoporosispatient carePediatricRheumatic Diseasetherapy

Related Articles

    Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

    November 14, 2021

    Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

    Osteoporosis Experts Discuss Bisphosphonate Holidays

    November 24, 2020

    ACR CONVERGENCE 2020—Bisphosphonates are an important treatment for millions of older Americans with osteoporosis because the drugs inhibit osteoclastic bone resorption to reduce the risk of painful, debilitating fractures.1 More than 20 years ago, data emerged that bisphosphonates have a long terminal half-life.2 So after years of therapy, could some patients take a drug holiday?…

    Unexpected Benefits of Bisphosphonates after Hip Fracture

    February 3, 2012

    Recent trials show this bisphosphonates can reduce subsequent hip fractures and mortality, while remaining cost effective.

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences